House Republicans: Community rating waivers need to remain in Senate’s ACA replacement

Conservatives in the House who had voted for the American Health Care Act (AHCA) in May are already displeased about rumored changes to the bill being considered by Senate Republicans.

Of particular interest is whether states could waive the ACA’s community rating provision. Included in the House bill, it was criticized for allowing the return of medical underwriting to individual policies, which could potentially price people with pre-existing conditions out of the market. The more moderate Senate may remove that waiver ability from their version of the Affordable Care Act replacement plan.

“It won’t pass the House,” Rep. Raul Labrador, R-Idaho, told the Independent Journal Review. “If we can’t give the states flexibility, I won’t support it.”

Differences between the House and Senate Republican caucuses have the potential to kill the AHCA. Senate leaders reportedly aim to pass their version of the AHCA by the end of June, leaving one month before the August recess to settle those differences in a conference committee.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.